Lithotripsy Device Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Growing Global Incidence of Kidney and Urinary Tract Stones

Stone disease prevalence is climbing across every major region due to diet shifts, sedentary habits, and dehydration patterns that potentiate mineral crystallization in urinary tracts. Shock-wave lithotripsy still posts 50–75% success among eligible patients, yet its limitations open room for modern devices that can address harder stones and wider patient profiles. Clinical trials report 88% fragmentation and nearly 49% stone-free status with burst-wave ultrasound, illustrating efficacy gains over legacy systems.^{[1]Source: Applied Radiology, “Portable Ultrasound Technology Found Safe, Effective for Treating Urinary Stones,” appliedradiology.com} Market demand consequently favors solutions that secure higher clearance in fewer sessions, reinforcing steady volume growth within the lithotripsy device market.

Continuous Technology Evolution Toward Non-Invasive, High-Precision Platforms

Thulium-fiber lasers, vortex-beam ultrasound, and optimized energy-delivery algorithms are rewriting device specifications and clinical protocols. Olympus’s SOLTIVE platform lowers procedure time by 20% and boosts fragmentation efficiency by 33% compared with Holmium YAG lasers.^{[2]Source: Olympus Medical Americas, “SOLTIVE SuperPulsed Laser System Shortens Kidney Stone Procedure Time,” medical.olympusamerica.com} Boston Scientific’s MOSES 2.0 reduces retropulsion by 50% and enables 90% same-day discharge, making it attractive for outpatient workflows.^{[3]Source: Boston Scientific, “MOSES 2.0 Technology for Lithotripsy,” bostonscientific.com} Academic prototypes such as Lithovortex showcase low-cost ultrasound designs that promise non-invasive fragmentation for broader patient cohorts. These advances help providers elevate outcomes while trimming anesthesia use, fueling premium-priced system demand across the lithotripsy device market.

Rising Adoption of Day-Care/Ambulatory Stone-Management Procedures

Ambulatory surgical centers (ASCs) receive incremental reimbursement support, including new pass-through codes for single-use ureteroscopes, which make outpatient stone removal economically viable. Ultrasound modalities capable of anesthesia-free treatment suit emergency departments and rapid-turnover clinics, slashing resource utilization while preserving outcomes. Consequently, device vendors are intensifying R&D into compact, plug-and-play systems that migrate lithotripsy volumes from inpatient suites to ASCs, expanding the lithotripsy device market footprint.

Expansion of Healthcare Infrastructure and Surgical Capacity in Emerging Economies

China’s policy drive to resolve hospital debt and revive procurement is restoring device purchasing budgets. India’s 2024 marketing code introduces clearer compliance standards, encouraging foreign entrants and transparent competition. Japan’s rapid uptake of thulium-fiber lasers underscores how Asia Pacific buyers adopt advanced platforms soon after launch. Robust infrastructure investment thus helps lift procedural capacity, drawing global manufacturers deeper into emerging-market channels and reinforcing CAGR expansion for the lithotripsy device market.

Adverse Post-ESWL Complications

Stone street formation and other side effects from shock-wave therapy remain clinical concerns, especially for lower-pole renal stones where flexible ureteroscopy achieves 90.2% stone-free rates versus ESWL’s 61.5%. Manufacturer exits from the ESWL segment and clinician shifts toward endoscopic modalities illustrate growing selectivity. Although burst-wave refinements may revitalize extracorporeal offerings, safety perceptions continue to cap ESWL spend within the lithotripsy device market.

High Upfront and Lifecycle Costs of Lithotripsy Systems

Capital intensity restricts procurement, with small hospitals deferring purchases or opting for rental models. EDAP TMS sold only 2 lithotripters in Q1 2024 versus 4 in the prior year, underscoring budget headwinds. The NIH summarizes that device reimbursement demands robust clinical evidence, adding time and expense to market entry. Leasing services, such as HealthTronics’ fleet, partly mitigate barriers but underline persistent affordability challenges that drag on lithotripsy device market growth.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Lithotripsy Device Market Segment Analysis

Extracorporeal shock-wave units captured 52.70% of lithotripsy device market share in 2025, yet intracorporeal platforms are forecast to rise at 5.74% CAGR through 2031. Laser-based systems, especially thulium-fiber models, fragment stones twice as quickly at half the power of earlier lasers, a performance win that has shifted hospital investment priorities. Electromagnetic ESWL devices keep traction in high-volume centers because of their procedural familiarity, while piezoelectric variants carve out specialized niches where precise energy targeting is essential.

Intracorporeal advances dovetail with the broader surgical trend toward precision and minimal tissue insult. Laboratory evidence shows 92% fragmentation under optimized settings, widening clinical acceptance of these tools. Ultrasonic lithotrites with aspiration enhance percutaneous workflows, and pneumatic devices persist in difficult cases needing mechanical impact. Collectively, these dynamics lift the intracorporeal portion of the lithotripsy device market while pushing vendors to diversify portfolios beyond legacy extracorporeal units.

Stand-alone suites held 65.05% of the lithotripsy device market size in 2025, anchored by well-equipped hospital units handling complex cases with integrated imaging. Yet portable and tabletop designs are pacing the modality race with a 6.08% CAGR. Break Wave ultrasound shows how mobility and anesthesia-free performance can broaden access to emergency departments and rural clinics. The Lithovortex prototype amplifies this shift by packaging vortex-beam capability into an affordable footprint suited for budget-restricted settings.

Operational flexibility is critical. Portable systems shorten room turnover, fit multi-department use, and lower facility overhead, making them popular with ASC administrators aiming for strong throughput. Vendors are thus engineering hybrid configurations—compact enough for transport yet robust enough to integrate with fluoroscopy—ensuring continued relevance across multiple care environments within the lithotripsy device market.

Kidney stones accounted for 57.74% of the lithotripsy device market size in 2025, but pancreatic stone treatment is advancing quickest at 6.62% CAGR as gastroenterologists embrace endoscopic ultrasound-guided lithotripsy. Bile-duct management also benefits from electrohydraulic energy delivered via cholangioscopes, adding procedure types to hospital offerings.

Ureteral and bladder applications remain staples in urology departments, where flexible scopes and laser fibers yield high stone-free ratios. Salivary-duct stone removal, though niche, is gaining traction in ENT settings thanks to miniaturized lithotripters. The widening array of anatomical indications is expanding device utilization hours, underpinning broader revenue prospects for the lithotripsy device market.

Hospitals retained 51.10% usage share in 2025, but ambulatory surgical centers (ASCs) are on a 6.86% CAGR trajectory. Transitional Pass-Through payments for single-use scopes lower capital thresholds, helping ASCs add stone-management lines without ballooning budgets. Specialty clinics concentrate domain expertise, streamlining scheduling and post-operative care.

Hospital systems are responding with hybrid care models that intertwine inpatient resources and outpatient efficiency, ensuring they remain referral hubs for complex presentations. Urgent-care sites and mobile units, grouped under “Others,” extend reach into communities with limited specialist access. Across these settings, demand converges on devices that marry clinical sophistication to workflow simplicity, reinforcing the growth outlook for the lithotripsy device market.

Geography Analysis

North America Lithotripsy Device Market

North America accounted for 32.21% of lithotripsy device market share in 2025, supported by transparent reimbursement pathways and a dense ASC network. Hospitals exploit Medicare coding stability to justify equipment refresh cycles, while vendors enjoy receptive early-adopter physician bases. The region’s robust after-sales service networks further safeguard utilization uptime, sustaining replacement demand.

Europe Lithotripsy Device Market

Europe follows with mature yet steadily modernizing health systems. National health funds encourage minimally invasive interventions, accelerating adoption of newer lasers and portable ultrasound. Cross-border purchasing frameworks support multicountry tenders that often favor vendors offering comprehensive training and maintenance, a factor strengthening pan-regional product footprints.

APAC, MEA and South America Lithotripsy Device Market

Asia Pacific is forecast to grow at 7.18% CAGR thanks to infrastructure expansion, regulatory reforms, and rising per-capita income. Japan’s USD 40 billion medical-device sector is investing heavily in IoT-enabled equipment that maximizes operating-room productivity. China’s debt-relief strategy is unblocking hospital CAPEX budgets, and India’s conduct code is fostering market transparency. Middle East & Africa plus South America trail in absolute value but are accelerating as new private hospitals and public-sector projects equip operating theaters, broadening the global footprint of the lithotripsy device market.

Regulatory Landscape

In the United States, extracorporeal shock wave lithotripters fall under FDA Class II device regulation (21 CFR 876.5990) and typically proceed through the 510(k) pathway, with FDA guidance shaping evidence requirements around shockwave generation, targeting/localization, and associated imaging components. For safety and performance demonstration, manufacturers commonly align technical files with FDA-recognized consensus standards such as IEC 60601-2-36 for extracorporeally induced lithotripsy equipment.

In Europe, lithotripsy systems are governed by the EU Medical Device Regulation (MDR) (EU) 2017/745, which remains in force as of January 2026, and many systems are assessed under MDR classification rules that often place them in Class IIb. Regulatory monitoring intensified after the European Commission released COM(2025)1023 on 16 December 2025 proposing amendments to MDR annexes, keeping conformity-assessment planning, clinical evaluation documentation, and legacy-device transition management in focus for suppliers selling across EU member states.

Market Opportunities and Future Outlook

Non-invasive, anesthesia-sparing ultrasound lithotripsy and adjunct fragment-management technologies open space for systems engineered around outpatient throughput and point-of-care deployment, rather than fixed-suite workflows. SonoMotion reported in May 2026 that its Break Wave pivotal S.O.U.N.D trial met primary endpoints supporting ultrasound-based stone fragmentation without anesthesia, and it also received FDA clearance for a next-generation Break Wave device with a smaller footprint intended for ambulatory and multi-department placement constraints. These steps keep near-term commercialization and procurement discussions centered on portability, room turnover, and reduced anesthesia burden.

Laser platform refresh and consolidation are another opportunity area as providers modernize intracorporeal toolchains for ureteroscopy and PCNL efficiency. BD introduced the Elyra Thulium Fiber Laser System in May 2026 in two configurations positioned for stone dusting workflows and reduced stone migration, while published work on pulsed thulium:YAG platforms adds options for buyers comparing ablation efficiency, retropulsion behavior, and service models. In parallel, FDA Breakthrough Device Designation granted to Avvio Medical for its Enhanced Lithotripsy System (ELS) in October 2025 highlights an innovation pathway aimed at non-invasive kidney stone treatment using microbubble-enhanced acoustic cavitation, indicating differentiated technology competition across procedure setting, patient experience, and total episode cost rather than energy modality alone.